Back to top
more

Iterum Therapeutics (ITRM)

(Delayed Data from NSDQ)

$1.58 USD

1.58
42,678

+0.03 (1.94%)

Updated Apr 23, 2024 04:00 PM ET

After-Market: $1.58 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (93 out of 252)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Iterum (ITRM) Plans Early Submission of UTI Drug NDA, Stock Up

by Zacks Equity Research

Iterum (ITRM) stock rises as the company gears up to submit a regulatory application to the FDA seeking approval for oral sulopenem to treat adult women with uUTIs ahead of schedule.

Avalo (AVTX) Fails to Meet Goal in Asthma Study, Stock Down 89%

by Zacks Equity Research

Avalo (AVTX) announces that it failed to meet the primary endpoint in its mid-stage poorly controlled non-eosinophilic asthma study. The stock falls 89% on Monday following the news.

Catalyst (CPRX) to Gain DMD Drug Licensing Rights From Santhera

by Zacks Equity Research

Catalyst (CPRX) announces entering into a definitive agreement to acquire licensing rights in North America to Santhera's DMD treatment candidate, vamorolone, which is currently under FDA review.

Abhinab Dasgupta headshot

Beat the Market the Zacks Way: Uber, VirTra, Oracle in Focus

by Abhinab Dasgupta

Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.

Baudax (BXRX) Up on New Neuromuscular Blocking Agent Study Data

by Zacks Equity Research

New data from Baudax's (BXRX) study on BX1000 confirms greater comparability of the highest dose of the candidate to the standard dose of rocuronium as a neuromuscular blockade. Stock gains 4%.

Nektar Therapeutics (NKTR) Q1 Earnings & Revenues Beat

by Zacks Equity Research

Nektar's (NKTR) Q1 loss is narrower than expected while revenues beat estimates.

Theravance's (TBPH) Q1 Earnings and Revenues Miss Estimates

by Zacks Equity Research

Thervance's (TBPH) first-quarter 2023 loss wider than expected. Revenues decline year over year and also miss estimates.

All You Need to Know About Iterum Therapeutics PLC (ITRM) Rating Upgrade to Strong Buy

by Zacks Equity Research

Iterum Therapeutics PLC (ITRM) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Iterum Therapeutics PLC (ITRM) Could Find Support Soon, Here's Why You Should Buy the Stock Now

by Zacks Equity Research

Iterum Therapeutics PLC (ITRM) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Iterum Therapeutics PLC (ITRM) Loses 67.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

by Zacks Equity Research

Iterum Therapeutics PLC (ITRM) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Company News for June 2, 2020

by Zacks Equity Research

Companies in the news are: MYOV, ITRM, COTY, OPK

Iterum Down as Sulopenem Antibiotic Fails in Phase III Study

by Zacks Equity Research

Iterum's antibiotic candidate, sulopenem, fails to meet the primary endpoint of non-inferiority to Merck's Invanz in a late-stage study, evaluating it in complicated intra-abdominal infections.

Iterum Therapeutics PLC (ITRM) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Iterum Therapeutics PLC (ITRM) delivered earnings and revenue surprises of -14.97% and -100.00%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Iterum Therapeutics PLC (ITRM) Q3 Earnings Expected to Decline

by Zacks Equity Research

Iterum Therapeutics PLC (ITRM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Iterum Therapeutics PLC (ITRM) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Iterum Therapeutics PLC (ITRM) delivered earnings and revenue surprises of -17.68% and -100.00%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Iterum Therapeutics PLC (ITRM) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

by Zacks Equity Research

Iterum Therapeutics PLC (ITRM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Iterum Therapeutics PLC (ITRM) Moves to Buy: Rationale Behind the Upgrade

by Zacks Equity Research

Iterum Therapeutics PLC (ITRM) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Will Iterum Therapeutics Continue to Surge Higher?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor in Iterum Therapeutics.